| 1 | patient outcomes and the | | | | | | | 2 | 0.57% |
| 2 | for more information related | | | | | | | 2 | 0.57% |
| 3 | bausch health companies inc | | | | | | | 2 | 0.57% |
| 4 | more information related to | | | | | | | 2 | 0.57% |
| 5 | bausch health recognizes that | | | | | | | 2 | 0.57% |
| 6 | quality of health care | | | | | | | 2 | 0.57% |
| 7 | nature bausch health is | | | | | | | 1 | 0.28% |
| 8 | concept” or “exploratory” in | | | | | | | 1 | 0.28% |
| 9 | of concept” or “exploratory” | | | | | | | 1 | 0.28% |
| 10 | not affiliated with our | | | | | | | 1 | 0.28% |
| 11 | bausch health is not | | | | | | | 1 | 0.28% |
| 12 | health is not the | | | | | | | 1 | 0.28% |
| 13 | is not the sponsor | | | | | | 1 | 0.28% |
| 14 | not the sponsor of | | | | | | 1 | 0.28% |
| 15 | the sponsor of these | | | | | | 1 | 0.28% |
| 16 | sponsor of these studies | | | | | | 1 | 0.28% |
| 17 | of these studies and | | | | | | | 1 | 0.28% |
| 18 | these studies and they | | | | | | | 1 | 0.28% |
| 19 | studies and they are | | | | | | | 1 | 0.28% |
| 20 | bausch health bausch | | | | | | | 1 | 0.28% |
| 21 | affiliated with our own | | | | | | | 1 | 0.28% |
| 22 | can produce important contributions | | | | | | | 1 | 0.28% |
| 23 | the therapeutic areas of | | | | | | | 1 | 0.28% |
| 24 | or the therapeutic areas | | | | | | | 1 | 0.28% |
| 25 | products or the therapeutic | | | | | | | 1 | 0.28% |
| 26 | healths products or the | | | | | | | 1 | 0.28% |
| 27 | important contributions regarding bausch | | | | | | | 1 | 0.28% |
| 28 | produce important contributions regarding | | | | | | | 1 | 0.28% |
| 29 | iiss can produce important | | | | | | | 1 | 0.28% |
| 30 | with our own clinical | | | | | | | 1 | 0.28% |
| 31 | that iiss can produce | | | | | | | 1 | 0.28% |
| 32 | believe that iiss can | | | | | | | 1 | 0.28% |
| 33 | development programs however we | | | | | | | 1 | 0.28% |
| 34 | clinical development programs however | | | | | | | 1 | 0.28% |
| 35 | own clinical development programs | | | | | | | 1 | 0.28% |
| 36 | “proof of concept” or | | | | | | | 1 | 0.28% |
| 37 | our own clinical development | | | | | | | 1 | 0.28% |
| 38 | and are “proof of | | | | | | | 1 | 0.28% |
| 39 | are “proof of concept” | | | | | | | 1 | 0.28% |
| 40 | grants click below investigatorinitiated | | | | | | | 1 | 0.28% |